Samsara Bio Capital, LLC Liquidia Corp Transaction History

Samsara Bio Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$4.86 - $11.44 $4.93 Million - $11.6 Million	-1,013,773 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.31 - $7.15 $183,066 - $395,445	55,307 Added 5.77%	1,013,773 $4.78 Million
Q4 2019 Feb 18, 2020	BUY	$3.07 - $5.11 $2.47 Million - $4.11 Million	804,004 Added 520.52%	958,466 $4.1 Million
Q3 2019 Nov 14, 2019	SELL	$3.29 - $8.24 $1.66 Million - $4.15 Million	-504,070 Reduced 76.54%	154,462 $550,000
Q2 2019 Aug 14, 2019	BUY	$7.92 - $11.39 $152,396 - $219,166	19,242 Added 3.01%	658,532 $5.27 Million
Q1 2019 May 15, 2019	BUY	$10.82 - $21.79 $2.82 Million - $5.68 Million	260,870 Added 68.94%	639,290 $7.28 Million
Q4 2018 Feb 14, 2019	BUY	$16.38 - $37.18 $6.2 Million - $14.1 Million	378,420 New	378,420 $8.2 Million

171

44.3M

1.55M

1.52M

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $685M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.